MUC1 and neoplasm: In MUC1-positive A549 cells (Figure 7A), BBiApt significantly enhanced CD16-positive cells’ cytotoxicity against tumor cells, while MUC1 aptamers or CD16 aptamers alone failed to generate a similar effect.